Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) Operating Expenses (2020 - 2025)

Oncology Institute's Operating Expenses history spans 6 years, with the latest figure at $148.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 32.68% year-over-year to $148.9 million; the TTM value through Dec 2025 reached $538.8 million, up 18.8%, while the annual FY2025 figure was $538.8 million, 18.8% up from the prior year.
  • Operating Expenses reached $148.9 million in Q4 2025 per TOI's latest filing, up from $144.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $148.9 million in Q4 2025 to a low of $50.3 million in Q1 2021.
  • Average Operating Expenses over 5 years is $98.8 million, with a median of $98.8 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: skyrocketed 56611.81% in 2021, then grew 1.49% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $93.1 million in 2021, then grew by 3.62% to $96.5 million in 2022, then increased by 4.74% to $101.1 million in 2023, then rose by 11.0% to $112.2 million in 2024, then skyrocketed by 32.68% to $148.9 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Operating Expenses are $148.9 million (Q4 2025), $144.6 million (Q3 2025), and $131.0 million (Q2 2025).